determination and the implementation of preventive, diagnostic or therapeutic medical
strategies. However, the ESC Guidelines do not override in any way whatsoever the …

Cancer-associated venous thrombosis is a common condition, although the reported
incidence varies widely between studies depending on patient population, start and duration …

Background Direct oral anticoagulants (DOACs) are an alternative to low-molecular-weight
heparin for treating cancer-associated VTE. Research Question Is rivaroxaban as efficient …

The task of developing ESC Guidelines covers not only the integration of the most recent
research, but also the creation of educational tools and implementation programmes for the …

This guidance document focuses on the diagnosis and treatment of venous
thromboembolism (VTE). Efficient, cost effective diagnosis of VTE is facilitated by combining …

The close relationship between cancer and thrombosis is known since more than a century.
Venous thromboembolism (VTE) may be the first manifestation of an occult malignancy in an …

Thrombosis can affect any venous circulation. Venous thromboembolism (VTE) includes
deep-vein thrombosis of the leg or pelvis, and its complication, pulmonary embolism. VTE is …

Venous thromboembolism (VTE) is categorized by the US Surgeon General as a major
public health problem. VTE is relatively common and associated with reduced survival and …

Cardio-oncology has organically developed as a new discipline within cardiovascular
medicine as a result of the cardiac and vascular adverse sequelae of the major advances in …

It takes about 3 months to complete “active treatment” of venous thromboembolism (VTE),
with further treatment serving to prevent new episodes of thrombosis (“pure secondary …